Selective noradrenergic vulnerability in α-synuclein transgenic mice

Area of Science:

• Neuroscience
• Pathology
• Genetics

Background:

• Parkinson's disease (PD) pathology involves dopaminergic and noradrenergic neuron loss, with Lewy bodies of alpha-synuclein (ASYN).
• Existing ASYN overexpression models often fail to replicate key PD features like significant dopaminergic deficits.

Purpose of the Study:

• To investigate the effects of mutant human ASYN (A53T) on catecholaminergic systems in transgenic mice.
• To determine if ASYN overexpression leads to neuronal loss or functional deficits in dopamine and norepinephrine pathways.

Main Methods:

• Utilized transgenic (Tg) mice expressing human ASYN (A53T) under the Prion promoter.
• Analyzed norepinephrine and dopamine levels in various brain regions and spinal cord.
• Assessed tyrosine hydroxylase (TH) protein levels and TH-positive terminals via immunohistochemistry in aged and young Tg mice compared to controls.

Main Results:

• Aged Tg mice showed significant norepinephrine reduction in spinal cord, olfactory bulb, and striatum, but not dopamine reduction.
• Age-dependent decrease in TH protein and terminals was observed in the spinal cord and olfactory bulb of aged Tg mice.
• No difference in the number of TH-positive neuron cell bodies in the substantia nigra (SN) or locus coeruleus (LC) between Tg and control mice.

Conclusions:

• Aberrant ASYN expression preferentially causes degeneration of noradrenergic terminals.
• The norepinephrine system appears more vulnerable than the dopamine system to toxic ASYN effects in this mouse model.
• Findings align with observed noradrenergic system damage in human Parkinson's disease patients.